Journal of thrombosis and haemostasis : JTH
-
J. Thromb. Haemost. · Nov 2017
Randomized Controlled TrialReversal of apixaban anticoagulation by four-factor prothrombin complex concentrates in healthy subjects: a randomized three-period crossover study.
Essentials Prothrombin complex concentrates (PCCs) may reverse the effect of factor Xa (FXa) inhibitors. We conducted an open-label, randomized, placebo-controlled, three-period crossover study in 15 subjects. Both PCCs rapidly reversed apixaban-mediated decreases in mean endogenous thrombin potential. Four-factor PCC administration had no effect on apixaban pharmacokinetics or anti-FXa activity.
-
J. Thromb. Haemost. · Nov 2017
Multicenter Study Observational StudyClinical course of patients with symptomatic isolated superficial vein thrombosis: the ICARO follow-up study.
Essentials Late sequelae of isolated superficial vein thrombosis (iSVT) have rarely been investigated. We studied 411 consecutive outpatients with acute iSVT with a median follow-up of three years. Male sex and cancer are risk factors for future deep vein thrombosis or pulmonary embolism. Patients without cancer appear to be at a negligible risk for death.
-
J. Thromb. Haemost. · Nov 2017
Randomized Controlled Trial Multicenter Study Comparative StudyEffect of late prophylaxis in hemophilia on joint status: a randomized trial.
Essentials High-quality data are lacking on use of prophylaxis in adults with hemophilia and arthropathy. SPINART was a 3-year randomized clinical trial of late/tertiary prophylaxis vs on-demand therapy. Prophylaxis improved function, quality of life, activity and pain but not joint structure by MRI. Prophylaxis improves function but must start before joint bleeding onset to prevent arthropathy.